Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18392953 | 0.76 | NOTUM (0.34) | NOTUMPARP10PARP11 | |
| SCHEMBL15870167 | 0.76 | HTR2A (0.37) | NOTUMPARP10PARP11 | |
| SCHEMBL3419324 | 0.73 | NOTUM (0.40) | NOTUMPARP10PARP11 | |
| SCHEMBL23771342 | 0.73 | CD44 (0.35) | — | |
| SCHEMBL14671492 | 0.72 | MAP4K1 (0.38) | NOTUM | |
| SCHEMBL25111467 | 0.72 | NOTUM (0.34) | NOTUM | |
| SCHEMBL19633371 | 0.72 | NOTUM (0.35) | NOTUMPARP10PARP11 | |
| SCHEMBL22311516 | 0.72 | GFER (0.33) | NOTUMPARP10PARP11 | |
| SCHEMBL30107339 | 0.72 | NOTUM (0.32) | NOTUMPARP10PARP11 | |
| SCHEMBL20365013 | 0.72 | NOTUM (0.32) | NOTUMPARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023030478-A1 | PYRIDOLACTAM DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2023-03-09 | — | — | WO | disclosed |
| WO-2022076975-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-10654836-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190161476-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | NOTUM 4350/4885PARP10 1884/4885PARP11 1702/4885 |
| US-10654836-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | FGFR4, FGFR1, FGFR2 | NOTUM 308/4885PARP10 1835/4885PARP11 1608/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | NOTUM 4350/4885PARP10 1884/4885PARP11 1702/4885 |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | NOTUM 4350/4885PARP10 1884/4885PARP11 1702/4885 |
| US-20190161476-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | FGFR4, FGFR1, FGFR2 | NOTUM 308/4885PARP10 1835/4885PARP11 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.